Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46

Imported from official source

Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.

This version

Version
1 of 1
Recorded
November 05, 2026 11:02
Change
Initial
Content hash
c4605e40389e671c327e587d5a94dcad
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.